Vanherweghem J L, Dhaene M, Tielemans C, Dratwa M, Verbanck P, Bergmann P, Schoutens A, Fuss M
Proc Eur Dial Transplant Assoc. 1981;18:648-51.
The usefulness of 99mTc-Pyrophosphate (99mTc-PPi) bone scintigraphy was evaluated in the follow up of 21 haemodialysed patients without clinical or radiological evidence of osteodystrophy. 99mTc-PPi bone scintigraphy was semi-quantitatively analysed using Fogelman's score. Patients were randomised to receive vitamin D analogues (1 alpha hydroxyvitamin D3 or dihydrotachysterol, n = 12) or to serve as controls (n = 9), both groups being given oral calcium supplements. Bone scintigraphy deteriorated in patients only on calcium therapy but not in patients treated by vitamin D-analogues. Vitamin D therapy reduced secondary hyperparathyroidism in all cases but induced rapid intoxication with normal doses in 4 of the 12 treated patients. Since intoxicated patients had significantly lower Fogelman's score than the patients who tolerated the treatment well, 99mTc-PPi bone scintigraphy is proposed as a screening test before vitamin D-analogues trials.
对21例无骨营养不良临床或放射学证据的血液透析患者进行随访,评估了99m锝焦磷酸盐(99mTc-PPi)骨闪烁显像的效用。采用福格尔曼评分对99mTc-PPi骨闪烁显像进行半定量分析。患者被随机分为两组,一组接受维生素D类似物(1α-羟基维生素D3或双氢速甾醇,n = 12)治疗,另一组作为对照组(n = 9),两组均给予口服钙剂。仅接受钙剂治疗的患者骨闪烁显像结果恶化,而接受维生素D类似物治疗的患者则未出现这种情况。维生素D治疗在所有病例中均降低了继发性甲状旁腺功能亢进,但在12例接受治疗的患者中有4例在使用正常剂量时出现了快速中毒。由于中毒患者的福格尔曼评分显著低于耐受良好的患者,因此建议在进行维生素D类似物试验之前,将99mTc-PPi骨闪烁显像作为一项筛查试验。